Phase I abuse liability trial of intranasally administered benzhydrocodone/paracetamol (KP 201), compared with hydrocodone/paracetamol.

Trial Profile

Phase I abuse liability trial of intranasally administered benzhydrocodone/paracetamol (KP 201), compared with hydrocodone/paracetamol.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Benzhydrocodone/paracetamol (Primary) ; Hydrocodone/paracetamol
  • Indications Pain
  • Focus Adverse reactions
  • Sponsors KemPharm
  • Most Recent Events

    • 12 Sep 2017 According to a company media release, KemPharm has responded to the Complete Response Letter (CRL) received on June 13, 2016 by submitting an amended New Drug Application (NDA) for Apadaz. The FDA has notified the Company with the determination that the NDA application for Apadaz is complete and has assigned February 23, 2018 as the expected date by which an approval decision will be determined.
    • 09 Sep 2016 According to a KemPharm media release, the results will be presented at the annual meeting PAINWeek 2016.
    • 08 Sep 2016 Results published in a KemPharm media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top